Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
14 July 2017
E-004841-17
Question for written answer
to the Commission
Rule 130
Soledad Cabezón Ruiz (S&D)

 Subject:  Research into diabetes and degeneration
 Answer(s) 

The last few years have seen an increase in the incidence of diabetes, both in the EU and worldwide. According to the latest WHO statistics, around 422 million people suffer from diabetes worldwide, a figure which could double in the next 20 years. According to the International Diabetes Federation (IDF), the number of diabetics in the EU will have risen to 38 million by 2030.

One of the long-term health complications caused by diabetes is damage to the retina which could result in blindness, therefore there needs to be research into diabetes and, particularly, into macular medical conditions. However, the framework programmes currently include precious little research into diabetes, and none whatsoever into diabetes or age-related macular degeneration. The most recent research into this was conducted under the Innovative Medicines Initiative (IMI) in 2015.

1. Does the Commission intend to initiate fresh research into diabetes and the related health complications?

2. Does the Commission also plan on investigating diabetes or age-related macular degeneration?

Original language of question: ES 
Last updated: 2 August 2017Legal notice